Preliminary and Annual Report to shareholders
Filed with ASX · · 63 pages · English
Record growth – Total revenue up 44%, Cash receipts up 94%, Thor Laboratories acquired, global structure established, two new device series for market in 2017, CIIC agreement targeting $65m over 5 years. SYDNEY, Australia, Wednesday 17th August 2016: Uscom Limited (ASX code: UCM) (the Company or Uscom), a revenue stage, cardiovascular medical devices company, today released to market its appendix
Earlier from Uscom
- Additional Uscom BP Plus US Patent
- New US Uscom BP Plus Patent
- Uscom agreement with CIIC Shanghai
- New Uscom BP Plus Distributor in Vietnam
- Oversubscribed PP for Strategic Investment
Later from Uscom
- Uscom Meets with Chinese Health Minister
- Uscom Budapest Revenue up 48%
- Paediatric Sepsis Outcomes Improved With USCOM
- CE Mark for New Uscom Asthma and COPD Devices
- Uscom Awarded Euro Grant for Lung Cancer Diagnostic
Follow Uscom into a list and get an email when it puts out news.
Follow Uscom